Stan Louie is a clinical and translational pharmacologist with over three decades of clinical and drug development experience. His research focus has been drug development for inflammatory diseases which include viral infections, cancer, diabetes, traumatic brain injuries and neurodegenerative diseases. His activities have included dissecting fundamental causes leading to diseases and developing drug therapies to manage these conditions.
A graduate of the University of California, San Francisco, in 1987, Louie continued his clinical training at California Pacific Medical Center. After his residency training, he accepted a position at University of Southern California, where he began his academic career investigating cancer therapy and bone marrow transplantation.
He is a translational scientist who advances new chemical and biological candidates through preclinical in vitro and animal evaluation, which ultimately progress these programs into human clinical trials. Currently the leader for the Center in Drug Discovery and Development at USC, he is forging efforts to translate basic science discovery into clinical reality. For these efforts, he has developed screening methods for each platform, and developed strategies to iteratively optimize the lead candidates into compounds possessing a balance between maximized stability, safety and pharmacokinetic profile.
His laboratory focuses on drug development for the treatment for autoimmunity, ocular injury, retinal degeneration, and neurodegeneration. Efforts in the laboratory cross a number of therapeutic areas including 1) drug development for inflammation and regeneration, 2) new chemical entity development targeting neural and retinal degeneration, 3) development of light activated drug (nanocaged) for the treatment of traumatic brain injury and ophthalmologic injury, and 4) modulators of chronic inflammation using bioactive lipids.
Currently, his laboratory is working on lipoxin-like compounds for the treatment of retinitis pigmentosa, aged-related macular degeneration, and autoimmune diseases (e.g. systemic lupus erythematous). In addition, his laboratory is translating the peptide modulators in the renin-angiotensin aldosterone system (RAAS). In this drug development, he has developed metabolomics and lipidomics assays that is able to quantify RAS peptides and bioactive lipids as potential biomarker development.